Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients
- PMID: 18450338
- DOI: 10.1016/j.vaccine.2008.03.054
Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients
Abstract
The current "gold standard" for generation of dendritic cell (DC) used in DC-based cancer vaccine studies is maturation of monocyte-derived DCs with tumor necrosis factor-alpha (TNF-alpha)/IL-1beta/IL-6 and prostaglandin E(2) (PGE(2)). Recently, a protocol for producing so-called alpha-Type-1 polarized dendritic cells (alphaDC1) in serum-free medium was published based on maturation of monocyte-derived DCs with TNF-alpha/IL-1-beta/polyinosinic:polycytidylic acid (poly-I:C)/interferon (IFN)-alpha and IFN-gamma. This DC maturation cocktail was described to fulfill the criteria for optimal DC generation and to be superior to the standard DC (sDC) cocktail as it induced fully mature DCs with potent IL-12p70 secretion together with CCR7 expression which is necessary for priming of a TH1 response and for migration to the draining lymph node, respectively. In this study, we tested the adaptation of alphaDC1 maturation cocktail to a protocol for clinical grade DC generation from cancer patients performed in X-VIVO 15 medium. We showed that alphaDC1 in this protocol induce lower up-regulation of CD83 and several other maturation markers, co-stimulatory molecules and CCR7 together with higher up-regulation of inhibitory molecules such as PD-L1, ILT2, ILT3 as compared to sDC. Although alphaDC1 matured DCs secreted more IL-12p70 and IL-23 these DCs had lower or similar stimulatory capacity compared to sDCs when used as stimulating cells in mixed lymphocyte reaction (MLR) or for induction of autologous influenza antigen specific T lymphocytes. Thus, our observations underline that alphaDC1 maturation cannot be directly adapted to alternative protocols for DC generation. Also, this study indicates the necessity for further investigation of correlation between in vitro DC parameters and their in vivo efficacy in clinical vaccination trials.
Similar articles
-
Uncarinic acid C plus IFN-γ generates monocyte-derived dendritic cells and induces a potent Th1 polarization with capacity to migrate.Cell Immunol. 2010;266(1):104-10. doi: 10.1016/j.cellimm.2010.09.004. Epub 2010 Sep 18. Cell Immunol. 2010. PMID: 20933226
-
The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization.Vaccine. 2007 Oct 10;25(41):7145-52. doi: 10.1016/j.vaccine.2007.07.031. Epub 2007 Aug 6. Vaccine. 2007. PMID: 17719152
-
Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine.Cancer Res. 2008 Jul 15;68(14):5965-71. doi: 10.1158/0008-5472.CAN-07-6494. Cancer Res. 2008. PMID: 18632652
-
Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines.Crit Rev Immunol. 2001;21(1-3):157-78. Crit Rev Immunol. 2001. PMID: 11642602 Review.
-
Cytokines in the generation and maturation of dendritic cells: recent advances.Eur Cytokine Netw. 2002 Apr-Jun;13(2):186-99. Eur Cytokine Netw. 2002. PMID: 12101074 Review.
Cited by
-
Addition of CpG ODN and Poly (I:C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacity.Hum Vaccin Immunother. 2015;11(7):1596-605. doi: 10.1080/21645515.2015.1046659. Hum Vaccin Immunother. 2015. PMID: 26039883 Free PMC article.
-
Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function.Blood. 2012 Mar 29;119(13):3113-22. doi: 10.1182/blood-2011-10-385930. Epub 2012 Feb 8. Blood. 2012. PMID: 22323449 Free PMC article.
-
IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives.Vaccines (Basel). 2020 Oct 19;8(4):617. doi: 10.3390/vaccines8040617. Vaccines (Basel). 2020. PMID: 33086492 Free PMC article. Review.
-
Dendritic cell subsets and implications for cancer immunotherapy.Front Immunol. 2024 Jun 5;15:1393451. doi: 10.3389/fimmu.2024.1393451. eCollection 2024. Front Immunol. 2024. PMID: 38903502 Free PMC article. Review.
-
Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma.Neurooncol Adv. 2022 Jun 24;4(1):vdac089. doi: 10.1093/noajnl/vdac089. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35967100 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials